Top

Published in:

Open Access 01-06-2017 | Review

The role of autoantibodies in the pathophysiology of rheumatoid arthritis

Authors: V. F. A. M. Derksen, T. W. J. Huizinga, D. van der Woude

Published in: Seminars in Immunopathology | Issue 4/2017

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), anti-carbamylated protein antibodies (anti-CarP), and more recently anti-acetylated protein antibodies RA can be subdivided into seropositive and seronegative disease. The formation of these autoantibodies is associated with both genetic and environmental risk factors for RA, like specific human leukocyte antigen (HLA) alleles and smoking. Autoantibodies can be detected many years before disease onset in a subset of patients, suggesting a sequence of events in which the first autoantibodies develop in predisposed hosts, before an inflammatory response ensues leading to clinically apparent arthritis. Research on the characteristics and effector functions of these autoantibodies might provide more insight in pathophysiological processes underlying arthritis in RA. Recent data suggests that ACPA might play a role in perpetuating inflammation once it has developed. Furthermore, pathophysiological mechanisms have been discovered supporting a direct link between the presence of ACPA and both bone erosions and pain in RA patients. In conclusion, investigating the possible pathogenic potential of autoantibodies might lead to improved understanding of the underlying pathophysiological processes in rheumatoid arthritis.

Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108. doi:10.1016/s0140-6736(10)60826-4 CrossRefPubMed

Shi J, Knevel R, Suwannalai P et al (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 108(42):17372–17377. doi:10.1073/pnas.1114465108 CrossRefPubMedPubMedCentral

Juarez M, Bang H, Hammar F et al (2016) Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75(6):1099–1107. doi:10.1136/annrheumdis-2014-206785 CrossRefPubMed

MacGregor AJ, Snieder H, Rigby AS et al (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43(1):30–37. doi:10.1002/1529-0131(200001)43:1<30::aid-anr5>3.0.co;2-b CrossRefPubMed

Huizinga TW, Amos CI, van der Helm-van Mil AH et al (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52(11):3433–3438. doi:10.1002/art.21385 CrossRefPubMed

Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30(11):1205–1213CrossRefPubMed

Hill JA, Southwood S, Sette A et al (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171(2):538–541CrossRefPubMed

Scally SW, Petersen J, Law SC et al (2013) A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 210(12):2569–2582. doi:10.1084/jem.20131241 CrossRefPubMedPubMedCentral

de Almeida DE, Ling S, Holoshitz J (2011) New insights into the functional role of the rheumatoid arthritis shared epitope. FEBS Lett 585(23):3619–3626. doi:10.1016/j.febslet.2011.03.035 CrossRefPubMedPubMedCentral

10.

Ling S, Cline EN, Haug TS et al (2013) Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum 65(3):618–626. doi:10.1002/art.37814 CrossRefPubMedPubMedCentral

11.

Diogo D, Okada Y, Plenge RM (2014) Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis: recent findings and challenges. Curr Opin Rheumatol 26(1):85–92. doi:10.1097/bor.0000000000000012 CrossRefPubMed

12.

Begovich AB, Carlton VE, Honigberg LA et al (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75(2):330–337. doi:10.1086/422827 CrossRefPubMedPubMedCentral

13.

Rieck M, Arechiga A, Onengut-Gumuscu S et al (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179(7):4704–4710CrossRefPubMed

14.

Chang HH, Liu GY, Dwivedi N et al (2016) A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. JCI Insight 1(17):e90045. doi:10.1172/jci.insight.90045 CrossRefPubMedPubMedCentral

15.

Makrygiannakis D, Hermansson M, Ulfgren AK et al (2008) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 67(10):1488–1492. doi:10.1136/ard.2007.075192 CrossRefPubMed

16.

Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38–46. doi:10.1002/art.21575 CrossRefPubMed

17.

Kallberg H, Padyukov L, Plenge RM et al (2007) Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80(5):867–875. doi:10.1086/516736 CrossRefPubMedPubMedCentral

18.

Snir O, Rieck M, Gebe JA et al (2011) Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 63(10):2873–2883. doi:10.1002/art.30445 CrossRefPubMedPubMedCentral

19.

James EA, Rieck M, Pieper J et al (2014) Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheum 66(7):1712–1722. doi:10.1002/art.38637 CrossRef

20.

Zhang X, Zhang D, Jia H (2015) The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 21(8):895–905. doi:10.1038/nm.3914 CrossRefPubMed

21.

Sandhya P, Danda D, Sharma D et al (2016) Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J Rheum Dis 19(1):8–20. doi:10.1111/1756-185x.12728 CrossRefPubMed

22.

Lundberg K, Kinloch A, Fisher BA et al (2008) Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 58(10):3009–3019. doi:10.1002/art.23936 CrossRefPubMed

23.

Farquharson D, Butcher JP, Culshaw S (2012) Periodontitis, Porphyromonas, and the pathogenesis of rheumatoid arthritis. Mucosal Immunol 5(2):112–120. doi:10.1038/mi.2011.66 CrossRefPubMed

24.

Konig MF, Abusleme L, Reinholdt J et al (2016) Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med 8(369):369ra176. doi:10.1126/scitranslmed.aaj1921 CrossRefPubMed

25.

Schellekens GA, de Jong BA, van den Hoogen FH et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101(1):273–281. doi:10.1172/jci1316 CrossRefPubMedPubMedCentral

26.

Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43(1):155–163. doi:10.1002/1529-0131(200001)43:1<155::aid-anr20>3.0.co;2-3 CrossRefPubMed

27.

van der Helm-van Mil AH, Verpoort KN, Breedveld FC et al (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949–R958. doi:10.1186/ar1767 CrossRefPubMedPubMedCentral

28.

Nordberg LB, Lillegraven S, Lie E et al (2017) Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naive patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis 76(2):341–345. doi:10.1136/annrheumdis-2015-208873 CrossRefPubMed

29.

Derksen VF, Ajeganova S, Trouw LA et al (2016) Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Ann Rheum Dis 76(4):716–720. doi:10.1136/annrheumdis-2016-209794 CrossRefPubMed

30.

Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA et al (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54(12):3799–3808. doi:10.1002/art.22279 CrossRefPubMed

31.

van Beers JJ, Schwarte CM, Stammen-Vogelzangs J et al (2013) The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum 65(1):69–80. doi:10.1002/art.37720 CrossRefPubMed

32.

Kuhn KA, Kulik L, Tomooka B et al (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116(4):961–973. doi:10.1172/jci25422 CrossRefPubMedPubMedCentral

33.

Scherer HU, van der Woude D, Ioan-Facsinay A et al (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62(6):1620–1629. doi:10.1002/art.27414 CrossRefPubMed

34.

Harre U, Lang SC, Pfeifle R et al (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651. doi:10.1038/ncomms7651 CrossRefPubMedPubMedCentral

35.

Hafkenscheid L, Bondt A, Scherer HU et al (2017) Structural analysis of variable domain glycosylation of anti-citrullinated protein antibodies in rheumatoid arthritis reveals the presence of highly sialylated glycans. Mol Cell Proteomics 16(2):278–287. doi:10.1074/mcp.M116.062919 CrossRefPubMed

36.

Wang Z, Nicholls SJ, Rodriguez ER et al (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13(10):1176–1184. doi:10.1038/nm1637 CrossRefPubMed

37.

Verheul MK, van Erp SJ, van der Woude D et al (2016) Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. Ann Rheum Dis 75(8):1575–1576. doi:10.1136/annrheumdis-2016-209248 CrossRefPubMed

38.

Ospelt C, Bang H, Feist E et al (2017) Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2016-210059 Published Online First: 09 February 2017 PubMed

39.

Jiang X, Trouw LA, van Wesemael TJ et al (2014) Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis 73(10):1761–1768. doi:10.1136/annrheumdis-2013-205109 CrossRefPubMed

40.

Ajeganova S, van Steenbergen HW, Verheul MK et al (2017) The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis 76(1):112–118. doi:10.1136/annrheumdis-2015-208870 CrossRefPubMed

41.

Simon GM, Cheng J, Gordon JI (2012) Quantitative assessment of the impact of the gut microbiota on lysine epsilon-acetylation of host proteins using gnotobiotic mice. Proc Natl Acad Sci U S A 109(28):11133–11138. doi:10.1073/pnas.1208669109 CrossRefPubMedPubMedCentral

42.

Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48(10):2741–2749. doi:10.1002/art.11223 CrossRefPubMed

43.

Nielen MM, van Schaardenburg D, Reesink HW et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50(2):380–386. doi:10.1002/art.20018 CrossRefPubMed

44.

Shi J, van de Stadt LA, Levarht EW et al (2014) Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 73(4):780–783. doi:10.1136/annrheumdis-2013-204154 CrossRefPubMed

45.

van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A et al (2010) Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 69(8):1554–1561. doi:10.1136/ard.2009.124537 CrossRefPubMed

46.

van de Stadt LA, de Koning MH, van de Stadt RJ et al (2011) Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 63(11):3226–3233. doi:10.1002/art.30537 CrossRefPubMed

47.

Kokkonen H, Mullazehi M, Berglin E et al (2011) Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 13(1):R13. doi:10.1186/ar3237 CrossRefPubMedPubMedCentral

48.

Sokolove J, Bromberg R, Deane KD et al (2012) Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 7(5):e35296. doi:10.1371/journal.pone.0035296 CrossRefPubMedPubMedCentral

49.

Brink M, Hansson M, Mathsson L et al (2013) Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 65(4):899–910. doi:10.1002/art.37835 CrossRefPubMed

50.

Rombouts Y, Ewing E, van de Stadt LA et al (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74(1):234–241. doi:10.1136/annrheumdis-2013-203565 CrossRefPubMed

51.

Suwannalai P, van de Stadt LA, Radner H et al (2012) Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 64(5):1323–1328. doi:10.1002/art.33489 CrossRefPubMed

52.

Suwannalai P, Britsemmer K, Knevel R et al (2014) Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 73(1):270–276. doi:10.1136/annrheumdis-2012-202615 CrossRefPubMed

53.

Cambridge G, Leandro MJ, Edwards JC et al (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48(8):2146–2154. doi:10.1002/art.11181 CrossRefPubMed

54.

Clavel C, Nogueira L, Laurent L et al (2008) Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 58(3):678–688. doi:10.1002/art.23284 CrossRefPubMed

55.

Laurent L, Clavel C, Lemaire O et al (2011) Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 70(6):1052–1059. doi:10.1136/ard.2010.142091 CrossRefPubMed

56.

Anquetil F, Clavel C, Offer G et al (2015) IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol 194(8):3664–3674. doi:10.4049/jimmunol.1402334 CrossRefPubMed

57.

Sokolove J, Johnson DS, Lahey LJ et al (2014) Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheum 66(4):813–821. doi:10.1002/art.38307 CrossRef

58.

Trouw LA, Haisma EM, Levarht EW et al (2009) Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 60(7):1923–1931. doi:10.1002/art.24622 CrossRefPubMed

59.

Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5(178):178ra140. doi:10.1126/scitranslmed.3005580 CrossRef

60.

Pratesi F, Dioni I, Tommasi C et al (2014) Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis 73(7):1414–1422. doi:10.1136/annrheumdis-2012-202765 CrossRefPubMed

61.

Corsiero E, Bombardieri M, Carlotti E et al (2016) Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Ann Rheum Dis 75(10):1866–1875. doi:10.1136/annrheumdis-2015-208356 CrossRefPubMed

62.

Hecht C, Englbrecht M, Rech J et al (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 74(12):2151–2156. doi:10.1136/annrheumdis-2014-205428 CrossRefPubMed

63.

van Steenbergen HW, Ajeganova S, Forslind K et al (2015) The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis. Ann Rheum Dis 74(1):e3. doi:10.1136/annrheumdis-2014-206623 CrossRefPubMed

64.

Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122(5):1791–1802. doi:10.1172/jci60975 CrossRefPubMedPubMedCentral

65.

Krishnamurthy A, Joshua V, Haj Hensvold A et al (2016) Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis 75(4):721–729. doi:10.1136/annrheumdis-2015-208093 CrossRefPubMed

66.

Wigerblad G, Bas DB, Fernades-Cerqueira C et al (2016) Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis 75(4):730–738. doi:10.1136/annrheumdis-2015-208094 CrossRefPubMed

67.

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219. doi:10.1056/NEJMra1004965 CrossRefPubMed

68.

Ballanti E, Perricone C, di Muzio G et al (2011) Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 10(10):617–623. doi:10.1016/j.autrev.2011.04.012 CrossRefPubMed

69.

Kuwabara T, Ishikawa F, Kondo M et al (2017) The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediat Inflamm 2017:3908061. doi:10.1155/2017/3908061 CrossRef

70.

Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46(2):183–196. doi:10.1016/j.immuni.2017.02.006 CrossRefPubMed

71.

Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. doi:10.1016/s0140-6736(16)30173-8 CrossRefPubMed

Title: The role of autoantibodies in the pathophysiology of rheumatoid arthritis
Authors: V. F. A. M. Derksen
T. W. J. Huizinga
D. van der Woude
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: Seminars in Immunopathology / Issue 4/2017
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-017-0627-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of autoantibodies in the pathophysiology of rheumatoid arthritis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Cardiovascular risk in patients with rheumatoid arthritis

Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies

Selected cytokine pathways in rheumatoid arthritis

Cellular and molecular perspectives in rheumatoid arthritis

Future therapeutic targets in rheumatoid arthritis?

Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page